Clinical trials: Cancer Treatment
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01390818
- Testing
- MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono
Tobacco Use Cessation
Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study
The goal of this research study is to learn about 2 different interactive methods that are designed to help people with HIV/AIDS stop smoking.
- Trial name
- NCT02302859
- Testing
- Nicotine Patch, Questionnaires, Pamphlet
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2.
- Trial name
- NCT00232479
- Testing
- trastuzumab, docetaxel and carboplatin in dose dense regimen
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Miami
Solid Tumours
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and GSK1120212 in subjects with BRAF V600E/K mutation…
- Trial name
- NCT01928940
- Testing
- dabrafenib, trametinib
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
This pilot clinical trial studies the side effects of anti-ESO (cancer/test antigen) murine T-cell receptor (mTCR)-transduced autologous peripheral blood lymphocytes and combination chemotherapy with cyclophosphamide and…
- Conditions
- HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT02774291
- Testing
- Aldesleukin, Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Albert Einstein College of Medicine
Bronchiectasis Adult, Mediastinal Lymphadenopathy
Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound
The purpose of this study is to assess if there is decrease in cough during flexible bronchoscopy and endobronchial ultrasound when different modes of lidocaine administration are used.
- Conditions
- Bronchiectasis Adult, Mediastinal Lymphadenopathy, Pneumonia, Chest--Diseases
- Trial name
- NCT03829618
- Testing
- Topical lidocaine, Nebuliser solution, Nebuliser Suspension
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Pain, Cancer
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
The purpose of this study is to evaluate the safety of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy.
- Trial name
- NCT00293020
- Testing
- BEMA Fentanyl
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- BioDelivery Sciences International
Stomach Neoplasm
RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
This is a phase II study to evaluate RAD001 (Everolimus) in terms of 4-month progression-free survival rate (primary end-point) and response rate, toxicity, and overall survival (secondary end-points) in patients with metastatic…
- Trial name
- NCT00729482
- Testing
- RAD001
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Asan Medical Center
Breast Cancer
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00265759
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 622 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myelogenous Leukemia - Chronic Phase
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior…
- Trial name
- AIM4CML (NCT04666259)
- Testing
- ABL001
- Where
- 26 sites in United States
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Oral Mucositis
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.
- Trial name
- NCT02013050
- Testing
- SGX942
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Soligenix
Carcinoma, Renal Cell
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma
- Trial name
- NCT00077974
- Testing
- SU011248
- Where
- 15 sites in United States
- Volunteers
- 106 people
- Sponsor
- Pfizer
Breast Cancer
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for…
- Trial name
- NEFERTT (NCT00915018)
- Testing
- Neratinib, Trastuzumab, Paclitaxel
- Where
- 195 sites in United States, Australia and 33 more
- Volunteers
- 479 people
- Sponsor
- Puma Biotechnology, Inc.
Pancreatic Cancer
An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed.
- Trial name
- NCT01782690
- Testing
- erlotinib, gemcitabine
- Where
- Germany
- Volunteers
- 338 people
- Sponsor
- Hoffmann-La Roche
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor treatment.
- Trial name
- NCT04047797
- Testing
- Ixazomib, Ixazomib Citrate, Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment.
- Trial name
- NCT00162123
- Testing
- Ipilimumab
- Where
- 58 sites in United States, Argentina and 16 more
- Volunteers
- 248 people
- Sponsor
- Bristol-Myers Squibb
Sarcoma
Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00072280
- Testing
- dactinomycin, cyclophosphamide, etoposide
- Where
- 74 sites in United States, Australia and 2 more
- Volunteers
- 7 people
- Sponsor
- Children's Oncology Group
Cancer of Prostate
De-implementation of Low Value Castration for Men With Prostate Cancer
This study will use a theory-based, mixed methods approach to identify, tailor and pilot two different de-implementation strategies that vary widely in delivery, impact, and expected results for reducing low value androgen…
- Trial name
- DeADT (NCT03579680)
- Testing
- ADT ORDER CHECK ATTESTATION (OR), PROVIDER SCRIPT (SC)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy.
- Trial name
- NCT00468546
- Testing
- MabThera/Rituxan, Methotrexate
- Where
- 115 sites in United States, Belgium and 9 more
- Volunteers
- 520 people
- Sponsor
- Hoffmann-La Roche
Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
This phase II trial studies how well giving irinotecan hydrochloride together with oxaliplatin and capecitabine works as first-line therapy in treating patients with metastatic or unresectable locally advanced small bowel cancer.
- Trial name
- NCT00433550
- Testing
- capecitabine, irinotecan hydrochloride, oxaliplatin
- Where
- 115 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.